Aspire Bariatrics is a medical device company that is revolutionizing the treatment of obesity with its non-surgical weight loss system, the AspireAssist. The AspireAssist was FDA approved in the United States in June 2016 based on a Randomized Clinical Trial at 10 leading institutions across the United States, including Brigham & Women's, Mayo Clinic, Northwestern University, University of Pennsylvania, Weill Cornell, and Washington University in St. Louis. The clinical study showed excellent safety and best-in-class weight loss results among endoscopic weight loss procedures. The AspireAssist is also CE-marked and commercially available the European Union, Middle East, and New Zealand. Learn more at aspirebariatrics.com